Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle

Ligia J. Dominguez, Amy J. Davidoff, Pothur R. Srinivas, Paul R Standley, Mary F. Walsh, James R. Sowers

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Metformin enhances peripheral insulin action and reduces blood pressure in hypertensive rats. Our group has previously reported that insulin and insulin-like growth factor I (IGF-I) attenuate both agonist-induced vascular smooth muscle cell (VSMC) contraction and associated increases in cytosolic free calcium ([Ca](i)). Thus, changes in insulin actions may explain in part metformin's vascular effects. However, metformin's mechanism of action at the vasculature had not been elucidated. Therefore, the purpose of this study was to determine whether metformin evokes alterations in VSMC insulin and IGF-I receptors, glucose transport, and/or [Ca](i). We quantitated hormone binding and tyrosine kinase (TK) activity in partially purified insulin and IGF-I receptors prepared from metformin-treated (100 μm) and control rat aortic VSMC in culture. Glucose transport was assessed by 2-deoxyglucose uptake. Metformin exposure for 24 h 1) increased basal TK activity (metformin, 3.49 ± 0.39; control, 1.77 ± 0.39 pmol 32P incorporated/mg protein; P < 0.01) without changes in insulin- or IGF-I-stimulated TK activity, 2) increased 2- deoxyglucose transport in a dose-dependent manner, 3) decreased insulin (P < 0.01) and IGF-I binding (P < 0.05), and 4) decreased thrombin-induced elevation in [Ca](i) (metformin, 10.3%; control, 35.3% over basal; P < 0.05). These insulin/IGF-I-like effects of metformin may help explain some of its vascular actions.

Original languageEnglish (US)
Pages (from-to)113-121
Number of pages9
JournalEndocrinology
Volume137
Issue number1
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Metformin
Vascular Smooth Muscle
Protein-Tyrosine Kinases
Calcium
Glucose
Insulin
Insulin-Like Growth Factor I
Smooth Muscle Myocytes
IGF Type 1 Receptor
Deoxyglucose
Blood Vessels
TYK2 Kinase
Muscle Contraction
Thrombin
Cell Culture Techniques
Hormones
Blood Pressure

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. / Dominguez, Ligia J.; Davidoff, Amy J.; Srinivas, Pothur R.; Standley, Paul R; Walsh, Mary F.; Sowers, James R.

In: Endocrinology, Vol. 137, No. 1, 1996, p. 113-121.

Research output: Contribution to journalArticle

Dominguez, Ligia J. ; Davidoff, Amy J. ; Srinivas, Pothur R. ; Standley, Paul R ; Walsh, Mary F. ; Sowers, James R. / Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. In: Endocrinology. 1996 ; Vol. 137, No. 1. pp. 113-121.
@article{535dc55e9a134fa9a0b599c7f118d82c,
title = "Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle",
abstract = "Metformin enhances peripheral insulin action and reduces blood pressure in hypertensive rats. Our group has previously reported that insulin and insulin-like growth factor I (IGF-I) attenuate both agonist-induced vascular smooth muscle cell (VSMC) contraction and associated increases in cytosolic free calcium ([Ca](i)). Thus, changes in insulin actions may explain in part metformin's vascular effects. However, metformin's mechanism of action at the vasculature had not been elucidated. Therefore, the purpose of this study was to determine whether metformin evokes alterations in VSMC insulin and IGF-I receptors, glucose transport, and/or [Ca](i). We quantitated hormone binding and tyrosine kinase (TK) activity in partially purified insulin and IGF-I receptors prepared from metformin-treated (100 μm) and control rat aortic VSMC in culture. Glucose transport was assessed by 2-deoxyglucose uptake. Metformin exposure for 24 h 1) increased basal TK activity (metformin, 3.49 ± 0.39; control, 1.77 ± 0.39 pmol 32P incorporated/mg protein; P < 0.01) without changes in insulin- or IGF-I-stimulated TK activity, 2) increased 2- deoxyglucose transport in a dose-dependent manner, 3) decreased insulin (P < 0.01) and IGF-I binding (P < 0.05), and 4) decreased thrombin-induced elevation in [Ca](i) (metformin, 10.3{\%}; control, 35.3{\%} over basal; P < 0.05). These insulin/IGF-I-like effects of metformin may help explain some of its vascular actions.",
author = "Dominguez, {Ligia J.} and Davidoff, {Amy J.} and Srinivas, {Pothur R.} and Standley, {Paul R} and Walsh, {Mary F.} and Sowers, {James R.}",
year = "1996",
doi = "10.1210/en.137.1.113",
language = "English (US)",
volume = "137",
pages = "113--121",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle

AU - Dominguez, Ligia J.

AU - Davidoff, Amy J.

AU - Srinivas, Pothur R.

AU - Standley, Paul R

AU - Walsh, Mary F.

AU - Sowers, James R.

PY - 1996

Y1 - 1996

N2 - Metformin enhances peripheral insulin action and reduces blood pressure in hypertensive rats. Our group has previously reported that insulin and insulin-like growth factor I (IGF-I) attenuate both agonist-induced vascular smooth muscle cell (VSMC) contraction and associated increases in cytosolic free calcium ([Ca](i)). Thus, changes in insulin actions may explain in part metformin's vascular effects. However, metformin's mechanism of action at the vasculature had not been elucidated. Therefore, the purpose of this study was to determine whether metformin evokes alterations in VSMC insulin and IGF-I receptors, glucose transport, and/or [Ca](i). We quantitated hormone binding and tyrosine kinase (TK) activity in partially purified insulin and IGF-I receptors prepared from metformin-treated (100 μm) and control rat aortic VSMC in culture. Glucose transport was assessed by 2-deoxyglucose uptake. Metformin exposure for 24 h 1) increased basal TK activity (metformin, 3.49 ± 0.39; control, 1.77 ± 0.39 pmol 32P incorporated/mg protein; P < 0.01) without changes in insulin- or IGF-I-stimulated TK activity, 2) increased 2- deoxyglucose transport in a dose-dependent manner, 3) decreased insulin (P < 0.01) and IGF-I binding (P < 0.05), and 4) decreased thrombin-induced elevation in [Ca](i) (metformin, 10.3%; control, 35.3% over basal; P < 0.05). These insulin/IGF-I-like effects of metformin may help explain some of its vascular actions.

AB - Metformin enhances peripheral insulin action and reduces blood pressure in hypertensive rats. Our group has previously reported that insulin and insulin-like growth factor I (IGF-I) attenuate both agonist-induced vascular smooth muscle cell (VSMC) contraction and associated increases in cytosolic free calcium ([Ca](i)). Thus, changes in insulin actions may explain in part metformin's vascular effects. However, metformin's mechanism of action at the vasculature had not been elucidated. Therefore, the purpose of this study was to determine whether metformin evokes alterations in VSMC insulin and IGF-I receptors, glucose transport, and/or [Ca](i). We quantitated hormone binding and tyrosine kinase (TK) activity in partially purified insulin and IGF-I receptors prepared from metformin-treated (100 μm) and control rat aortic VSMC in culture. Glucose transport was assessed by 2-deoxyglucose uptake. Metformin exposure for 24 h 1) increased basal TK activity (metformin, 3.49 ± 0.39; control, 1.77 ± 0.39 pmol 32P incorporated/mg protein; P < 0.01) without changes in insulin- or IGF-I-stimulated TK activity, 2) increased 2- deoxyglucose transport in a dose-dependent manner, 3) decreased insulin (P < 0.01) and IGF-I binding (P < 0.05), and 4) decreased thrombin-induced elevation in [Ca](i) (metformin, 10.3%; control, 35.3% over basal; P < 0.05). These insulin/IGF-I-like effects of metformin may help explain some of its vascular actions.

UR - http://www.scopus.com/inward/record.url?scp=0030029042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030029042&partnerID=8YFLogxK

U2 - 10.1210/en.137.1.113

DO - 10.1210/en.137.1.113

M3 - Article

C2 - 8536601

AN - SCOPUS:0030029042

VL - 137

SP - 113

EP - 121

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 1

ER -